RBC Capital’s Brian Abrahams just told Vertex shareholders to hold their horses—literally. Despite Vertex stock closing at ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $448.40 Wednesday, on what proved to be an all-around rough trading ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What Are Smart ...

RBC Capital slightly trimmed Vertex Pharmaceuticals’ price target from $423 to $420, but the firm’s rating stayed the course.

This was the stock's third consecutive day of losses.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Dottie Caplan, who previously served as Senior Vice President, Patient Advocacy and Engagement, will be responsible for leading Applied’s patient engagement and advocacy efforts as well as the ...

Nearly $30 million in tax incentive awards are expected to add 1,519 new life sciences jobs in Massachusetts, with about 52% ...

Saudi biotech startup Novo Genomics signed two major agreements: one with Tracer Biotechnologies to localize ctDNA monitoring ...

Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his ...